Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 10/20 | 0.72 |
| ▸ | IKBKB | O14920 | 2/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.55 |
| ▸ | PRKACA | P17612 | 1/20 | 0.55 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.55 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.55 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.55 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.55 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.55 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.55 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.55 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.55 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.50 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2500597 | 0.99 | ROCK1 (0.70) | ROCK1IKBKBROCK2PRKACAPRKCD | |
| SCHEMBL3372945 | 0.90 | ROCK1 (0.57) | ROCK1IKBKBROCK2PRKACAPRKCD | |
| SCHEMBL18318650 | 0.90 | ROCK1 (0.59) | ROCK1IKBKBROCK2PRKACAPRKCD | |
| SCHEMBL26958653 | 0.86 | ROCK1 (0.55) | ROCK1IKBKBROCK2PRKCDKCNH2 | |
| Hydrochloric Acid SCHEMBL26928467 | 0.85 | ROCK1 (0.54) | ROCK1IKBKBROCK2PRKCDKCNH2 | |
| SCHEMBL4003522 | 0.85 | ROCK1 (0.74) | ROCK1IKBKBROCK2PRKCDKCNH2 | |
| SCHEMBL4007564 | 0.84 | ROCK1 (1.00) | ROCK1IKBKBROCK2PRKACAPRKCD | |
| Sar-407899 Free Base SCHEMBL8934240 | 0.84 | ROCK1 (0.72) | ROCK1IKBKBROCK2PRKACAPRKCD | |
| SCHEMBL2337345 | 0.84 | ROCK1 (0.54) | ROCK1IKBKBROCK2PRKACAPRKCD | |
| SCHEMBL2337348 | 0.84 | ROCK1 (0.54) | ROCK1IKBKBROCK2PRKACAPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722671-B2 | Isoquinoline derivatives | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-8722671-B2 | Isoquinoline derivatives | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-8501736-B2 | Isoquinoline derivatives | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-8501736-B2 | Isoquinoline derivatives | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| EP-2385047-B1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI SA (FR) | 2013-05-29 | — | — | EP | disclosed |
| EP-1910333-B1 | PIPERIDINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI SA (FR) | 2013-05-22 | — | — | EP | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| EP-2385047-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI (FR) | 2011-11-09 | — | — | EP | disclosed |
| US-20110245248-A1 | ISOQUINOLINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-10-06 | — | — | US | disclosed |
| US-20110245248-A1 | ISOQUINOLINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-10-06 | — | — | US | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090088429-A1 | Isoquinoline Derivatives | SANOFI-AVENTIS (FR) | 2009-04-02 | — | — | US | disclosed |
| US-20090088429-A1 | Isoquinoline Derivatives | SANOFI-AVENTIS (FR) | 2009-04-02 | — | — | US | disclosed |
| WO-2007012421-A1 | PIPERIDINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007000240-A1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF RHO-KINASE | SANOFI-AVENTIS (DE) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | MYLK2, MYLK, RHOT2 | ROCK1 8/4885IKBKB 606/4885ROCK2 10/4885 |
| US-20110245248-A1 | ISOQUINOLINE DERIVATIVES | MYLK2, MYLK, RHOT2 | ROCK1 7/4885IKBKB 866/4885ROCK2 5/4885 |
| US-20090088429-A1 | Isoquinoline Derivatives | MYLK2, MYLK, RHOT2 | ROCK1 7/4885IKBKB 866/4885ROCK2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.